Neal Rosen

54.5k citations

255 papers · 34.8k indexed · 13 hit papers · h-index 100

Molecular Biology top 0.05%
Oncology top 0.05%
Pulmonary and Respiratory Medicine top 0.2%
Cancer Research top 0.2%
Pathology and Forensic Medicine top 0.1%

Co-authors: David B. Solit Andrea Basso Poulikos I. Poulikakos Laura Sepp‐Lorenzino Sarat Chandarlapaty Qing‐Bai She Maurizio Scaltriti Gideon Bollag
Topics: Melanoma and MAPK Pathways (56 papers)PI3K/AKT/mTOR signaling in cancer (53 papers)Heat shock proteins research (44 papers)
Cited by: Oncology Molecular Biology Cancer Research
Journals: Nature Science New England Journal of Medicine
Partner nations: United States United Kingdom Spain

In The Last Decade

Neal Rosen

249 papers receiving 34.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

2006 2.0k citations Qing‐Bai She, David B. Solit et al. Cancer Research profile →
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

2010 1.3k citations Neal Rosen et al. profile →
Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent

1997 1.2k citations Neal Rosen et al. profile →
BRAF mutation predicts sensitivity to MEK inhibition

2005 1.0k citations David B. Solit, Christine A. Pratilas et al. profile →
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

2011 890 citations Sarat Chandarlapaty, Howard I. Scher et al. profile →
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

2011 746 citations Sarat Chandarlapaty, Ayana Sawai et al. profile →
Targeted drug delivery strategies for precision medicines

2021 738 citations Neal Rosen et al. profile →
Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function

2002 524 citations Andrea Basso, David B. Solit et al. profile →
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

2016 457 citations Piro Lito, Martha Solomon et al. Science profile →
Tumor adaptation and resistance to RAF inhibitors

2013 417 citations Piro Lito, Neal Rosen et al. profile →
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

2012 410 citations Piro Lito, Christine A. Pratilas et al. profile →
Therapy-induced tumour secretomes promote resistance and tumour progression

2015 364 citations Neal Rosen et al. profile →
BRAF — a tumour-agnostic drug target with lineage-specific dependencies

2024 57 citations Aphrothiti J. Hanrahan, Neal Rosen et al. profile →

Peers

Countries citing papers authored by Neal Rosen

Since Specialization

Citations

This map shows the geographic impact of Neal Rosen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neal Rosen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neal Rosen more than expected).

Fields of papers citing papers by Neal Rosen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neal Rosen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neal Rosen. The network helps show where Neal Rosen may publish in the future.

Co-authorship network of co-authors of Neal Rosen

This figure shows the co-authorship network connecting the top 25 collaborators of Neal Rosen. A scholar is included among the top collaborators of Neal Rosen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neal Rosen. Neal Rosen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties 2018 ·Cancer Discovery ·Yijun Gao,Matthew T. Chang,Daniel J. McKay,Na Na,Bing Zhou,Rona Yaeger,Neilawattie M. Torres,(unknown),Matthias Drosten,Mariano Barbacid,Giordano Caponigro,Darrin D. Stuart,Henrik Moebitz,David B. Solit,Omar Abdel‐Wahab,Barry S. Taylor,Zhan Yao,Neal Rosen	87
2	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition 2017 ·Cancer Research ·Rona Yaeger,Zhan Yao,David M. Hyman,Jaclyn F. Hechtman,Efsevia Vakiani,HuiYong Zhao,Wenjing Su,Lu Wang,Andrew Joelson,Andrea Cercek,José Baselga,Elisa de Stanchina,Leonard B. Saltz,Michael F. Berger,David B. Solit,Neal Rosen	60
3	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells 2016 ·Cancer Immunology Research ·Elliott J. Brea,Claire Y. Oh,Eusebio Manchado,Sadna Budhu,Ron S. Gejman,George Mo,Patrizia Mondello,James E. Han,Casey A. Jarvis,David Ulmert,Qing Xiang,Aaron Y. Chang,Ralph Garippa,Taha Merghoub,Jedd D. Wolchok,Neal Rosen,Scott W. Lowe,David A. Scheinberg	128
4	Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanismbreakdown → 2016 ·Science ·Piro Lito,Martha Solomon,Lian‐Sheng Li,Rasmus Hansen,Neal Rosen	457
5	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer 2015 ·Cancer Discovery ·(unknown),Chunxiao Xu,Sharmeen Uddin,Marzia Capelletti,Dalia Ercan,Atsuko Ogino,Christine A. Pratilas,Neal Rosen,Nathanael S. Gray,Kwok‐Kin Wong,Pasi A. Jänne	159
6	Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients 2015 ·Clinical Cancer Research ·Rona Yaeger,Andrea Cercek,Eileen M. O’Reilly,Diane Reidy‐Lagunes,Nancy E. Kemeny,(unknown),Marinela Capanu,Marc J. Gollub,Neal Rosen,Michael F. Berger,Mario E. Lacouture,Efsevia Vakiani,Leonard B. Saltz	221
7	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies 2014 ·Cancer Discovery ·Omar Abdel‐Wahab,Virginia M. Klimek,(unknown),Agnès Viale,Donavan T. Cheng,Eun Hee Kim,Raajit K. Rampal,Mark J. Bluth,James J. Harding,Margaret K. Callahan,Taha Merghoub,Michael F. Berger,David B. Solit,Neal Rosen,Ross L. Levine,Paul B. Chapman	59
8	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence 2014 ·Cancer Research ·Moriah H. Nissan,Christine A. Pratilas,Alexis M. Jones,Ricardo J. Ramirez,Helen Won,Cailian Liu,Shakuntala Tiwari,Li Ren Kong,Aphrothiti J. Hanrahan,Zhan Yao,Taha Merghoub,Antoni Ribas,Paul B. Chapman,Rona Yaeger,Barry S. Taylor,Nikolaus Schultz,Michael F. Berger,Neal Rosen,David B. Solit	219
9	Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders 2014 ·Cancer Discovery ·David M. Hyman,Eli L. Diamond,Cecile Rose T. Vibat,(unknown),Jason C. Poole,Minal Patel,Veronica R. Holley,Goran Cabrilo,Timothy T. Lu,Maria E. Arcila,Young Rock Chung,Raajit K. Rampal,Mario E. Lacouture,Neal Rosen,Funda Meric‐Bernstam,José Baselga,Razelle Kurzrock,Mark G. Erlander,Filip Jankú,Omar Abdel‐Wahab	84
10	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor 2013 ·Cancer Immunology Research ·Margaret K. Callahan,Gregg Masters,Christine A. Pratilas,Charlotte E. Ariyan,Jessica Katz,Shigehisa Kitano,(unknown),Ruth Ann Gordon,Shachi Vyas,Jianda Yuan,Ashok Gupta,Jon M. Wigginton,Neal Rosen,Taha Merghoub,Maria Jure‐Kunkel,Jedd D. Wolchok	91
11	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma 2013 ·Clinical Cancer Research ·Federica Catalanotti,David B. Solit,Melissa Pulitzer,Michael F. Berger,Sasinya N. Scott,Tunç Iyriboz,Mario E. Lacouture,Katherine S. Panageas,Jedd D. Wolchok,Richard D. Carvajal,Gary K. Schwartz,Neal Rosen,Paul B. Chapman	112
12	Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation 2011 ·Cancer Research ·Huisheng Wang,Sherif Daouti,Wenhui Li,Wen Yang,(unknown),Brian Higgins,Kathryn Packman,Neal Rosen,John F. Boylan,David Heimbrook,Huifeng Niu	62
13	Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET -Amplified Tumor Cells with or without Resistance to Selective MET Inhibition 2011 ·Clinical Cancer Research ·Thomas Bachleitner‐Hofmann,Mark Y. Sun,Chin‐Tung Chen,David Liska,Zhaoshi Zeng,Agnès Viale,Adam B. Olshen,Martina Mittlboeck,James G. Christensen,Neal Rosen,David B. Solit,Martin R. Weiser	33
14	Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice 2011 ·Proceedings of the National Academy of Sciences ·Aime T. Franco,Roberta Malaguarnera,Samuel Refetoff,Xiao-Hui Liao,Emma T. Lundsmith,Shioko Kimura,Catrin Pritchard,Richard Marais,Terry F. Davies,Lee S. Weinstein,Min Chen,Neal Rosen,Ronald Ghossein,Jeffrey A. Knauf,James A. Fagin	177
15	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab 2011 ·Clinical Cancer Research ·Shanu Modi,Alison Stopeck,Hannah Linden,David B. Solit,Sarat Chandarlapaty,Neal Rosen,Gabriella D’Andrea,Maura N. Dickler,Mary Ellen Moynahan,Steven Sugarman,Weining Ma,Sujata Patil,Larry Norton,Alison L. Hannah,Clifford A. Hudis	328
16	Genomic Complexity and AKT Dependence in Serous Ovarian Cancer 2011 ·Cancer Discovery ·Aphrothiti J. Hanrahan,Nikolaus Schultz,Maggie L. Westfal,Rita A. Sakr,Dilip D. Giri,(unknown),(unknown),Narciso Olvera,Ellen V. Stevens,Qing‐Bai She,Carol Aghajanian,Tari A. King,Elisa de Stanchina,David R. Spriggs,Adriana Heguy,Barry S. Taylor,Chris Sander,Neal Rosen,Douglas A. Levine,David B. Solit	88
17	Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer 2009 ·Cancer Research ·Derek S. Welsbie,Jin Xu,Yu Chen,Laetitia Borsu,Howard I. Scher,Neal Rosen,Charles L. Sawyers	144
18	^V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway 2009 ·Proceedings of the National Academy of Sciences ·Christine A. Pratilas,Barry S. Taylor,Qing Ye,Agnès Viale,Chris Sander,David B. Solit,Neal Rosen	455
19	Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel 2008 ·Cancer Research ·Ayana Sawai,Sarat Chandarlapaty,Heidi Greulich,Mithat Gönen,Qing Ye,Carlos L. Arteaga,William R. Sellers,Neal Rosen,David B. Solit	145
20	V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors 2005 ·Proceedings of the National Academy of Sciences ·Olivera M. Grbovic,Andrea Basso,Ayana Sawai,(unknown),Philip Friedlander,David B. Solit,Neal Rosen	228

About Neal Rosen

Neal Rosen is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine, having authored 255 papers that have together received 34.8k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (56 papers), PI3K/AKT/mTOR signaling in cancer (53 papers) and Heat shock proteins research (44 papers). The work is most often cited by research in Oncology (12.2k citations), Molecular Biology (24.7k citations) and Cancer Research (4.2k citations). Neal Rosen has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include David B. Solit, Andrea Basso, Poulikos I. Poulikakos, Laura Sepp‐Lorenzino, Sarat Chandarlapaty, Qing‐Bai She, Maurizio Scaltriti, Gideon Bollag, Gabriela Chiosis and José Baselga. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact